drugset
drugset / Trial / NCT06531941

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

NCT06531941 ↗

Phase 2 Active not recruiting 60 enrolled MBX Biosciences
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.

Timeline

Start
2024-10-31
Primary completion
2027-05-27
Completion
2027-05-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Canvuparatide Protein / enzyme biologic 200 ug Subcutaneous
Subject Canvuparatide Protein / enzyme biologic 400 ug Subcutaneous
Subject Canvuparatide Protein / enzyme biologic 1600 ug Subcutaneous

Indications

hypoparathyroidism